 | • レポートコード：TPM-NV161 • 出版社/出版日：Transparency Market Research / 2019年10月28日 • レポート形態：英文、PDF、171ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、脳卒中治療の世界市場について調べ、脳卒中治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、種類別（虚血性脳卒中および出血性脳卒中）分析、薬物クラス別（組織プラスミノーゲン活性化因子（tPA）、抗凝固薬、抗血小板薬、抗痙攣薬、その他）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、関連企業情報などをまとめました。 ・脳卒中治療の市場概要 ・脳卒中治療の市場動向 ・脳卒中治療の世界市場規模・予測 ・脳卒中治療市場：種類別（虚血性脳卒中および出血性脳卒中） ・脳卒中治療市場：薬物クラス別（組織プラスミノーゲン活性化因子（tPA）、抗凝固薬、抗血小板薬、抗痙攣薬、その他） ・脳卒中治療市場：薬物クラス別（組織プラスミノーゲン活性化因子（tPA）、抗凝固薬、抗血小板薬、抗痙攣薬、その他） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
Healthcare providers are recommending the consumption of non-vitamin K oral anticoagulants over commercially available medications such as Warfarin to reduce the incidence of atrial fibrillation in the stroke treatment market space. These efficacious oral anticoagulants are increasingly catching the attention of consumers and healthcare providers, as they effectively minimize the formation of clots in the blood. This is validated, as the revenue of anticoagulants amongst all drugs in the stroke treatment market is projected to hold the second-highest position, with a value of ~US$ 4.2 billion by 2027.
Oral anticoagulants are serving the convenience of stroke patients, as they can regularize any potential symptoms in home care settings. Thus, new oral anticoagulants are creating incremental opportunities for hospital, retail, and online pharmacies, as users can request for bulk orders at any given time. Healthcare companies in the stroke treatment market are developing improved formulations that make anticoagulants safer and help in reducing the risk of internal bleeding.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Stroke Treatment Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Stroke Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Key Industry Developments
5.2. Pipeline Analysis
5.3. Epidemiology Analysis
6. Global Stroke Treatment Market Value and Forecast, by Type
6.1. Introduction & Definition
6.2. Global Stroke Treatment Market Value Forecast, by Type, 2017–2027
6.2.1. Ischemic Stroke
6.2.2. Hemorrhagic Stroke
6.3. Global Stroke Treatment Market Attractiveness, by Type
7. Global Stroke Treatment Market Value and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Global Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
7.2.1. Tissue Plasminogen Activator (tPA)
7.2.2. Anticoagulants
7.2.3. Antiplatelets
7.2.4. Anticonvulsants
7.2.5. Others
7.3. Global Stroke Treatment Market Attractiveness, by Drug Class
8. Global Stroke Treatment Market Value and Forecast, by Distribution Channel
8.1. Introduction
8.2. Global Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.3. Global Stroke Treatment Market Attractiveness, by Distribution Channel
9. Global Stroke Treatment Market Value and Forecast, by Region
9.1. Introduction
9.2. Stroke Treatment Market Value Forecast, by Region, 2017–2027
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Stroke treatment Market Attractiveness, by Region
10. North America Stroke Treatment Market Analysis and Forecast
10.1. Introduction
10.2. North America Stroke Treatment Market Value Forecast, by Type, 2017–2027
10.2.1. Ischemic Stroke
10.2.2. Hemorrhagic Stroke
10.3. North America Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
10.3.1. Tissue Plasminogen Activator (tPA)
10.3.2. Anticoagulants
10.3.3. Antiplatelets
10.3.4. Anticonvulsants
10.3.5. Others
10.4. North America Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America Stroke treatment Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Stroke Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Europe Stroke Treatment Market Value Forecast, by Type, 2017–2027
11.2.1. Ischemic Stroke
11.2.2. Hemorrhagic Stroke
11.3. Europe Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
11.3.1. Tissue Plasminogen Activator (tPA)
11.3.2. Anticoagulants
11.3.3. Antiplatelets
11.3.4. Anticonvulsants
11.3.5. Others
11.4. Europe Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Stroke treatment Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Stroke Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Stroke Treatment Market Value Forecast, by Type, 2017–2027
12.2.1. Ischemic Stroke
12.2.2. Hemorrhagic Stroke
12.3. Asia Pacific Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
12.3.1. Tissue Plasminogen Activator (tPA)
12.3.2. Anticoagulants
12.3.3. Antiplatelets
12.3.4. Anticonvulsants
12.3.5. Others
12.4. Asia Pacific Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Stroke treatment Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Stroke Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Latin America Stroke Treatment Market Value Forecast, by Type, 2017–2027
13.2.1. Ischemic Stroke
13.2.2. Hemorrhagic Stroke
13.3. Latin America Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
13.3.1. Tissue Plasminogen Activator (tPA)
13.3.2. Anticoagulants
13.3.3. Antiplatelets
13.3.4. Anticonvulsants
13.3.5. Others
13.4. Latin America Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Stroke treatment Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Stroke treatment Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa Stroke Treatment Market Value Forecast, by Type, 2017–2027
14.2.1. Ischemic Stroke
14.2.2. Hemorrhagic Stroke
14.3. Middle East & Africa Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
14.3.1. Tissue Plasminogen Activator (tPA)
14.3.2. Anticoagulants
14.3.3. Antiplatelets
14.3.4. Anticonvulsants
14.3.5. Others
14.4. Middle East & Africa Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Stroke treatment Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Global Stroke Treatment Market Position Analysis, by Company, 2018
15.2. Company Profiles
15.2.1. Bristol-Myers Squibb Company
15.2.1.1. Company Description
15.2.1.2. Business Overview
15.2.1.3. Financial Overview
15.2.1.4. Strategic Overview
15.2.1.5. SWOT Analysis
15.2.2. Boehringer Ingelheim GmbH
15.2.2.1. Company Description
15.2.2.2. Business Overview
15.2.2.3. Financial Overview
15.2.2.4. Strategic Overview
15.2.2.5. SWOT Analysis
15.2.3. Daiichi Sankyo Company, Limited
15.2.3.1. Company Description
15.2.3.2. Business Overview
15.2.3.3. Financial Overview
15.2.3.4. Strategic Overview
15.2.3.5. SWOT Analysis
15.2.4. F. Hoffmann-La Roche Ltd
15.2.4.1. Company Description
15.2.4.2. Business Overview
15.2.4.3. Financial Overview
15.2.4.4. Strategic Overview
15.2.4.5. SWOT Analysis
15.2.5. Johnson & Johnson Services, Inc.
15.2.5.1. Company Description
15.2.5.2. Business Overview
15.2.5.3. Financial Overview
15.2.5.4. Strategic Overview
15.2.5.5. SWOT Analysis
15.2.6. Sanofi
15.2.6.1. Company Description
15.2.6.2. Business Overview
15.2.6.3. Financial Overview
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. Amgen, Inc.
15.2.7.1. Company Description
15.2.7.2. Business Overview
15.2.7.3. Financial Overview
15.2.7.4. Strategic Overview
15.2.7.5. SWOT Analysis
15.2.8. Biogen Inc.
15.2.8.1. Company Description
15.2.8.2. Business Overview
15.2.8.3. Financial Overview
15.2.8.4. Strategic Overview
15.2.8.5. SWOT Analysis
15.2.9. AstraZeneca
15.2.9.1. Company Description
15.2.9.2. Business Overview
15.2.9.3. Financial Overview
15.2.9.4. Strategic Overview
15.2.9.5. SWOT Analysis